Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2000-05-10
2008-12-16
Tran, S. (Department: 1618)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S451000, C424S457000, C424S459000, C424S464000, C424S468000, C424S490000, C424S493000, C424S494000, C424S495000
Reexamination Certificate
active
07465462
ABSTRACT:
A multiparticulate controlled release selective serotonin reuptate inhibitor (SSRI) formulation for oral administration is provided. The formulation includes particles of an SSRI or a pharmaceutically acceptable salt thereof, which are coated with a rate-controlling polymer that allows controlled release of the SSRI over a period of not less than about 12 hours after oral administration. The rate controlling polymer includes a film-forming water-insoluble polymer, or a mixture of a film-forming water-insoluble polymer and a film-forming water-soluble polymer.
REFERENCES:
patent: 4085225 (1978-04-01), Welle et al.
patent: 4851228 (1989-07-01), Zentner et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5271946 (1993-12-01), Hettche
patent: 5445829 (1995-08-01), Paradissis et al.
patent: 5776969 (1998-07-01), James
patent: 5948440 (1999-09-01), Arora et al.
patent: 5958458 (1999-09-01), Norling et al.
patent: 6066339 (2000-05-01), Stark et al.
patent: 6080736 (2000-06-01), Landry et al.
patent: 6183780 (2001-02-01), Van Balken et al.
patent: 6306436 (2001-10-01), Chungi et al.
patent: 6458384 (2002-10-01), Jaenicke et al.
patent: 6482440 (2002-11-01), Zemlan et al.
patent: 0 797 991 (1997-10-01), None
patent: 0 797 991 (1997-10-01), None
patent: 2 325 623 (1998-12-01), None
patent: 2 325 623 (1998-12-01), None
patent: 97 03670 (1997-02-01), None
patent: 99 01121 (1999-01-01), None
patent: 99 01122 (1999-01-01), None
patent: WO 9901122 (1999-01-01), None
patent: WO 9912524 (1999-03-01), None
Davidson, Jonathan et al, “Fluvoxamine-Controlled Release Formulation for the Treatment of Generalized Social Anxiety Disorder,” J. Clin. Psychopharmacol, vol. 24(2), pp. 118-125, Apr. 2004.
Westenberg, Herman et al , “A Double-Blind Placebo-Controlled Study of Controlled Release Fluvoxamine for the Treatment of Generalized Social Anxiety Disorder,” Journal of Clinical Psychopharmacology, vol. 24(1), pp. 49-55, Feb. 2004.
Hollander, Eric et al , “A Double-Blind Placebo-Controlled Study of the Efficacy and Safety of Controlled-Release Fluvoxamine in Patients With Obsessive-Compulsive Disorder,” J. Clin. Psychiatry, 64:6, pp. 640-647, Jun. 2003.
Jeary Theresa Ann
Morrissey Catherine Ann
Stark Paul
Elan Pharma International Limited
Fox Rothschild LLP
Tran S.
LandOfFree
Multiparticulate controlled release selective serotonin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multiparticulate controlled release selective serotonin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multiparticulate controlled release selective serotonin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4026653